HomeProgrammeProgramme At-a-glance

Programme At-a-glance

ILCA 15th Annual Conference Scientific Programme

The ILCA AC 2021 scientific programme will offer to participants with a large of different sessions dedicated to better prevent and treat liver cancer.

Scientific and medical experts from around the world will exchange the latest scientific advances and best practices in liver cancer research and care.

The 15th multidisciplinary Annual Conference format will present a mix of scientific and educational session and live debates and presentations.

A glance to some of the sessions that the ILCA Leadership is preparing:

Basic and Clinical Science Symposia

ILCA Debates with pro/cons arguments

State of the Art Sessions

General Sessions based on abstracts submissions

Single Topic Workshop dedicated sessions

Tumor Board Presentations

Poster Presentations

Rare liver tumours workshop

Fibrolamellar Carcinoma

Clinical aspects of fibrolamellar hepatocellular carcinoma

Ghassan K. Abou-Alfa, Medical Oncologist, Memorial Sloan Kettering Cancer Center, NY, US





Basic/Translation aspects of fibrolamellar hepatocellular carcinoma

Sandford Simon, Professor Biochemistry, biophysics, chemical biology and structural biology, The Rockefeller University, NY, US



Basic aspect of the hepatoblastoma

Jessica Zucman-Rossi, Professor of Medicine in Oncology, Director, Centre de Recherche des Cordeliers, Paris, France







Patient Advocacy

Patient advocacy for patients with fibrolamellar HCC

Mark Furth, Scientific Director, Fibrolamellar Cancer Foundation, Greenwich, US

Clinical State of the Art

Past, present and future of transplant oncology

Vincenzo Mazzaferro, Professor of Surgery at the Department of Oncology, University of Milan and Director of the Gastro-Intestinal Surgery and Liver Transplantation Unit at the Istituto Nazionale Tumori (National Cancer Institute) of Milan, Italy.

Basic State of the Art

Telomeres and cancer

Maria Blasco, Director of the Spanish National Cancer Research Centre (CNIO). Head of the Telomeres and Telomerase Group – CNIO, Madrid, Spain

Basic Science Symposium

What has single cell genomics contributed to our understanding of liver cancer?

Single cell genomics and response to therapies in hepatocellular carcinoma

Xin Wei Wang, Senior Investigator and Deputy Chief, Laboratory of Human Carcinogenesis. Co-Director, Liver Cancer Program
Center for Cancer Research National Cancer Institute, NIH, Bethesda, US





Ploidy heterogeneity and HCC prevention

Hao Zhu, Associate Professor, Children’s Research Institute at UT Southwestern, Dallas, US

Copyright © ILCA 2021